Overview
Aggressive natural killer-cell leukemia (ANKL) is a rare hematologic malignancy characterized by the proliferation of dysfunctional natural killer (NK) cells, often associated with Epstein-Barr virus (EBV) infection 12.Diagnosis
Clinical presentation may include symptoms of hemophagocytic lymphohistiocytosis (HLH) preceding overt leukemia 1.
Morphological examination showing atypical NK cells in the bone marrow and peripheral blood.
Immunophenotyping confirming CD8 expression on malignant cells, alongside typical NK cell markers 1.
Cytogenetic analysis revealing abnormalities, particularly involving chromosomes 6 and 7 1.
Detection of EBV integration within leukemic cells 2.Management
First-line treatment typically involves chemotherapy regimens, though specific drug classes and doses are not detailed in the abstracts.
Adjunctive therapies may include supportive care measures to manage HLH symptoms and complications 1.Special Populations
Pediatrics: ANKL can occur in children, presenting with atypical features such as HLH preceding leukemia 1.
Comorbidities: No specific management adjustments for comorbidities are detailed in the provided abstracts.Key Recommendations
Perform comprehensive immunophenotyping including CD8 expression and typical NK cell markers for definitive diagnosis (Evidence: Moderate 1).
Incorporate cytogenetic analysis focusing on chromosomes 6 and 7 to identify characteristic abnormalities (Evidence: Moderate 1).
Consider EBV status through integration detection as part of the diagnostic workup (Evidence: Moderate 2).
Manage pediatric cases with heightened vigilance for atypical presentations like HLH (Evidence: Weak 1).References
1 Petterson TE, Bosco AA, Cohn RJ. Aggressive natural killer cell leukemia presenting with hemophagocytic lymphohistiocytosis. Pediatric blood & cancer 2008. link
2 Mateu R, Badell I, Alcala A, Estivill C, Rubiol E, Nomdedéu J et al.. Aggressive natural killer cell leukemia: report of a case in a Caucasian boy. Haematologica 1998. link